Showing posts with label abstract. Show all posts
Showing posts with label abstract. Show all posts

Sunday, November 8, 2026

Broad #vaccine #protection against globally diverse #influenza #H5Nx viruses

 


Summary

Influenza A/H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide. The severity of human infections varies substantially between different H5 clades and neuraminidase (NA) reassortants, creating unpredictable pandemic risk. Existing H5 vaccines, typically based on a single hemagglutinin (HA) strain, cannot keep pace with this natural variation. To address this problem, we computationally engineer HA, NA, and M2 antigens representing the global antigenic space of circulating H5Nx viruses, prioritizing N1 and N6 subtypes associated with the highest threat in humans. The resulting digitally immune-optimized mRNA vaccine, DVX-panH5Nx, elicits broad HA neutralization and NA inhibition across divergent clades in mice and ferrets. Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.


Source: Cell Reports Medicine Journal, https://doi.org/10.1016/j.xcrm.2026.103131

____

Immunogenicity and #safety of two priming doses of an MF59-adjuvanted cell-based #H5N8 #influenza #vaccine in healthy persons aged ≥18 years



Abstract

Background

Increased transmission of avian influenza from animals to humans has elevated the risk of an H5 pandemic.

Methods

This phase 2, randomized, observer-blind, multi-center trial assessed the immunogenicity and safety of homologous priming with an MF59-adjuvanted, cell-based H5N8 A/Astrakhan/3212/2020 clade 2.3.4.4b vaccine (aH5N8c). We enrolled adults age ≥18 years, equally stratified into 18–64 (including a poultry-worker subset) and ≥65 year cohorts. Primary and secondary outcomes were homologous antibody responses against H5N8 measured in all participants by hemagglutination inhibition (HI) and in a subset by microneutralization (MN) assays on Days 1, 22, and 43. Solicited adverse events (AEs) were monitored for 7 days post-vaccination, with unsolicited AEs tracked throughout Day 43.

Results

239 participants were vaccinated (18–64 years, n = 121; ≥65 years, n = 118). At Day 43 (21 days post second aH5N8c dose), geometric mean fold increases (GMFI) were 13.7 for the 18–64 cohort and 10.2 for the ≥65 cohort. HI seroconversion rates were 75.8% (95% CI 66.1–83.8%) for the 18–64 cohort and 71.0% (61.1–79.6%) for the ≥65 cohort. HI titers ≥1:40 were achieved in 75.8% (66.1–83.8%) and 73.0% (63.2–81.4%) of participants, respectively. MN seroconversion rates were 80.6% (68.6–89.6%) and 70.0% (56.8–81.2%), while MN titers ≥1:40 were 83.9% (72.3–92.0%) and 86.7% (75.4–94.1%), respectively. No notable differences in immune responses by poultry worker status were observed. Most solicited AEs were mild or moderate, resolving within 3 days. Unsolicited AEs were reported by 16.7% participants by Day 43.

Conclusion

These data support the use of the MF59-adjuvanted, cell-based monovalent H5N8 vaccine as a public health intervention against H5 influenza.


Source: Vaccine Journal, https://doi.org/10.1016/j.vaccine.2026.129279

____

#Antigenic #landscape of a highly mutated #SARS-CoV-2 #spike in ongoing viral #evolution

 


Abstract

The ongoing emergence of SARS-CoV-2 variants in an increasingly immune-experienced population is largely enabled by the plasticity of the Spike protein, which lies at the frontline of host immune pressure. Here, we investigated how extensive remodeling of the N-terminal domain (NTD) in Spike influences its antigenic properties. Using BA.2.87.1, a variant heavily mutated in this domain, we found that even large deletions do not substantially disrupt overall Spike structure or pseudovirus infectivity. However, our structural and binding analyses revealed that the NTD exhibits increased flexibility and that interaction with a heme–metabolite, known to facilitate the exposure of an immunodominant epitope, is lost. These conformational effects, coupled with 33 NTD mutations, compromised the ability of human convalescent antibodies to engage this domain, contributing to their reduced neutralizing capacity. Consequently, BA.2.87.1-like variants may escape recognition by the preexisting NTD-targeting antibodies, potentially reducing protection. Together, our results highlight the intrinsic adaptability of the Spike beyond the receptor-binding domain, with implications for immune escape during viral evolution.


Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2608185123

____

Structure of #influenza D virus #NS1 reveals a novel Zn-binding site and ssRNA-binding activity

 


Abstract

Influenza D virus (IDV) is an emerging pathogen associated with bovine respiratory disease and has potential for zoonotic transmission. Although nonstructural protein 1 (NS1) is a major virulence factor in influenza A and B viruses, the structure and function of IDV NS1 remain poorly defined. Here, we determined crystal structures of the IDV NS1 N-terminal RNA-binding domain (NTD) and C-terminal effector domain (CTD). The NTD retains the conserved homodimeric six-helix fold, whereas the CTD adopts a distinct architecture containing a novel Zn²⁺-binding site. IDV NS1 CTD preferentially binds single-stranded RNA, and mutagenesis identified lysine and arginine residues critical for this activity. Single-residue substitutions disrupting either the Zn²⁺-binding site or RNA-binding interface prevented recovery of infectious recombinant IDV. These findings reveal distinct structural and functional features of IDV NS1 and establish the importance of CTD integrity for viral replication. Conservation of key CTD residues in influenza C virus NS1 suggests shared structural features that distinguish influenza C and D virus NS1 proteins from their influenza A and B counterparts.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Welch Foundation, https://ror.org/00np6vq88, C-1565


Source: BioRxIV, https://doi.org/10.64898/2026.10.29.760789

____

Saturday, November 7, 2026

A single–amino acid difference between #rodent and #human #Andes virus affects viral #glycoprotein trafficking

 


Abstract

Andes virus (ANDV) causes hantavirus pulmonary syndrome (HPS), with rare outbreaks involving person-to-person transmission. A human ANDV isolate from one such outbreak and a rodent isolate from the same region differ in lethality in Syrian golden hamsters. Genomic analysis revealed 25 nonsynonymous substitutions, including one leading to a T641I change in the human ANDV glycoprotein precursor near its cleavage site. Although the isolates differed in growth kinetics, strand-specific RT-qPCR did not support major differences in viral RNA synthesis, whereas virion release was delayed in the case of the human isolate. In human cell expression systems, a single I641T substitution in the human ANDV glycoprotein resulted in decreased Golgi retention and faster release of virion-like particles relative to wild-type glycoprotein. Since ANDV egress takes place at the Golgi, the T641I change present in the human ANDV isolate may represent a human adaptive mutation influencing glycoprotein trafficking and virus particle release.


Source: Science Advances Journal, https://doi.org/10.1126/sciadv.aek2522

____

#Coronavirus Disease Research #References (AMEDEO, Nov. 7 '26)

 


    Ann Intern Med

  1. REEDER HT, Donohue SE, Martin JN, Hornig M, et al
    Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants.
    Ann Intern Med. 2026 Nov 3. doi: 10.7326/ANNALS-25-05275.
    PubMed         Abstract available


    Antiviral Res

  2. LU Y, Yang S, Hou M, Yu L, et al
    4-octyl itaconate inhibits porcine epidemic diarrhea virus replication by modulating the ferroptosis axis and the autophagy pathway.
    Antiviral Res. 2026;255:106535.
    PubMed         Abstract available


    Int J Infect Dis

  3. LU M, Qiao M, Chen S, Zhu J, et al
    Human metapneumovirus-associated ARI hospitalisation rates in comparison to respiratory syncytial virus and influenza in eastern China, 2020-2024: a time-series analysis.
    Int J Infect Dis. 2026 Nov 5:109235. doi: 10.1016/j.ijid.2026.109235.
    PubMed         Abstract available

  4. COLOSI E, Calmon L, Fassli M, Koch KN, et al
    Pooled testing for SARS-CoV-2 surveillance in schools: evaluation of transmission control, testing resources, and educational disruption.
    Int J Infect Dis. 2026 Nov 4:109233. doi: 10.1016/j.ijid.2026.109233.
    PubMed         Abstract available

  5. KOK J, Bott L, Wiid Z, Williamson A, et al
    The Impact of Socioeconomic and Geographic Factors in Respiratory Virus Testing in Australia.
    Int J Infect Dis. 2026 Oct 31:109210. doi: 10.1016/j.ijid.2026.109210.
    PubMed         Abstract available


    J Med Virol

  6. ZETUM ASS, Silva DRCD, Ventorim VDP, Mion FA, et al
    Deciphering Host Genomic Pathway Landscapes in Severe COVID-19 by Exome Sequencing of a Large Admixed Brazilian Cohort.
    J Med Virol. 2026;98:e71193.
    PubMed         Abstract available


    J Virol

  7. BIRD B, Thorn L, Aminisani N, Wood T, et al
    Incidence and risk factors of acute respiratory illness associated with influenza, COVID-19, and respiratory syncytial virus within a birth cohort study.
    J Virol. 2026 Nov 6:e0086326. doi: 10.1128/jvi.00863.
    PubMed         Abstract available

  8. FRIEMAN MB, Menachery VD
    Outstanding scientific talent devoted to consequential problems.
    J Virol. 2026 Nov 5:e0145126. doi: 10.1128/jvi.01451.
    PubMed         Abstract available

  9. LACASSE E, Dubuc I, Leclerc J, Gravel A, et al
    SARS-CoV-2 Nsp2 reprograms host immunity to drive pathogenic inflammation.
    J Virol. 2026 Nov 5:e0133326. doi: 10.1128/jvi.01333.
    PubMed         Abstract available

  10. ZHANG Y, Bai B, Tang Y, Wang C, et al
    PEDV NSP5 promotes immune evasion by recruiting TRIM28 to degrade DDX3X.
    J Virol. 2026 Nov 4:e0151026. doi: 10.1128/jvi.01510.
    PubMed         Abstract available


    Lancet Infect Dis

  11. HAPPLE C, Hoffmann M, Stankov MV, Chen N, et al
    Humoral immunity after mRNA SARS-CoV-2 XFG vaccination.
    Lancet Infect Dis. 2026 Nov 5:S1473-3099(26)00569.
    PubMed        


    Nature

  12. FIELDHOUSE R
    The surprising reason women in academia do more parenting than men.
    Nature. 2026 Nov 5. doi: 10.1038/d41586-026-03568.
    PubMed        


    Science

  13. HANSEN CH, Lipstein M, Erlandson SC, Schwalbe T, et al
    Discovering molecular modulators with nanoswitch screening.
    Science. 2026;394:eadt7185.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Nov. 7 '26)

 


    Antiviral Res

  1. NAGAHAWATTA DP, Jeong SH, Liyanage NM, Jayawardena TU, et al
    Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
    Antiviral Res. 2026 Sep 15:106532. doi: 10.1016/j.antiviral.2026.106532.
    PubMed         Abstract available


    Arch Virol

  2. DANILENKO AV, Svyatchenko SV, Bragina MK, Goncharova NI, et al
    Characterization of influenza A(H3N2) viruses detected on a pig farm in Russia in 2017-2018.
    Arch Virol. 2026;171:314.
    PubMed         Abstract available


    BMC Pediatr

  3. ESTEVES L, Raymundo CE, de Andrade Medronho R
    Associated factors for COVID-19 mortality among children and adolescents in Rio de Janeiro state, 2020-2023.
    BMC Pediatr. 2026;26:1087.
    PubMed         Abstract available

  4. CHEN T, Guo X, Tang W, Liu F, et al
    Clinical characteristics and risk factors for poor prognosis of RSV lower respiratory tract infection: a two-center study.
    BMC Pediatr. 2026;26:1085.
    PubMed         Abstract available


    Epidemiol Infect

  5. LAU JY, Pan WC, Ji DD
    Transmission-route-specific trends in communicable diseases in Taiwan: an interrupted time-series analysis.
    Epidemiol Infect. 2026;154:e146.
    PubMed         Abstract available


    J Exp Med

  6. SUN R, Lin S, Simonelli L, Strunz B, et al
    Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1.
    J Exp Med. 2026;223:e20260268.
    PubMed         Abstract available


    J Infect Dis

  7. MEEKER JR, Price AM, Martin E, Vaughn I, et al
    Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016-17 Through 2024-25.
    J Infect Dis. 2026 Oct 31:jiag538. doi: 10.1093.
    PubMed         Abstract available


    J Neurosurg Pediatr

  8. ROBERTS CR, Jin R, Parker M, Spader HS, et al
    A decade of change in pediatric intracranial abscess surgery: rising volumes and evolving care (2013-2023).
    J Neurosurg Pediatr. 2026;38:642-648.
    PubMed         Abstract available


    J Virol

  9. BIRD B, Thorn L, Aminisani N, Wood T, et al
    Incidence and risk factors of acute respiratory illness associated with influenza, COVID-19, and respiratory syncytial virus within a birth cohort study.
    J Virol. 2026 Nov 6:e0086326. doi: 10.1128/jvi.00863.
    PubMed         Abstract available


    Pediatrics


  10. Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Policy Statement.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079045.
    PubMed         Abstract available


  11. Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079049.
    PubMed         Abstract available


  12. Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Technical Report.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079046.
    PubMed         Abstract available


  13. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079047.
    PubMed         Abstract available

  14. ESTEBAN RIERA I, Perez-Caballero R, Natalini Martinez S, Gonzalez-Amores M, et al
    Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents.
    Pediatrics. 2026 Oct 23:e2026076225. doi: 10.1542/peds.2026-076225.
    PubMed         Abstract available

  15. HIGGINS DM, Gurfinkel D, Dorsey B, O'Leary ST, et al
    Frontline Staff Vaccine Communication During Pediatric Well-Child Encounters: A Mixed-Methods Study.
    Pediatrics. 2026 Oct 23:e2026077450. doi: 10.1542/peds.2026-077450.
    PubMed         Abstract available


    PLoS Comput Biol

  16. LEBATTEUX D, Corso F, Soudeyns H, Boucoiran I, et al
    KmerSignificance score: A discriminative and biologically informed framework for viral k-mer prioritization.
    PLoS Comput Biol. 2026;22:e1014332.
    PubMed         Abstract available


    PLoS Med

  17. BENJAMIN H, Barnsley G, Watson OJ, Jit M, et al
    Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation.
    PLoS Med. 2026;23:e1004772.
    PubMed         Abstract available

  18. GAVISH N, Huppert A
    Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study.
    PLoS Med. 2026;23:e1004992.
    PubMed         Abstract available


    PLoS One

  19. WANG S, Xia Z, Shi B, Chen M, et al
    Weekly dynamics, subtype replacement and regional heterogeneity of influenza activity in China, 2024-2026: A national sentinel surveillance analysis.
    PLoS One. 2026;21:e0361588.
    PubMed         Abstract available

  20. ALKADI MM, Abuhelaiqa EA, Abdul Rahman RM, Mahgoub AB, et al
    Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients.
    PLoS One. 2026;21:e0359640.
    PubMed         Abstract available

  21. SVENSSON A, Sonnerfors P, Holmstrom L, Nygren-Bonnier M, et al
    Experiences of individually tailored physical exercise in COVID-19-induced postural orthostatic tachycardia syndrome: A qualitative content analysis.
    PLoS One. 2026;21:e0360748.
    PubMed         Abstract available

  22. ZHAO X, Deng L, Ford ND, Saydah S, et al
    Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity.
    PLoS One. 2026;21:e0345433.
    PubMed         Abstract available

  23. CANIZALES GALAVIZ J, Khan A, Tourki B, Patarroyo-White S, et al
    eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression.
    PLoS One. 2026;21:e0360244.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  24. SCHOWE AM, Ruks M, Disselkamp CKL, Kuznetsov DV, et al
    Epigenetic aging during the COVID-19 pandemic: A prospective longitudinal study with prepandemic baseline data in children, adolescents, and adults.
    Proc Natl Acad Sci U S A. 2026;123:e2604211123.
    PubMed         Abstract available

  25. CHARLESWORTH TES, Doyle MC, Banaji MR
    Patterns of implicit and explicit attitudes V: Increases in bias from 2021 to 2025.
    Proc Natl Acad Sci U S A. 2026;123:e2619420123.
    PubMed         Abstract available

  26. ZAPF AJ, Dewey G, Ognyanova K, Baum MA, et al
    Trust as a hidden driver of epidemic-relevant behavior: Institution- and behavior-specific associations across 20 national survey waves.
    Proc Natl Acad Sci U S A. 2026;123:e2622260123.
    PubMed         Abstract available


    Vaccine

  27. TRAN S, McClymont E, Blitz S, Barrett J, et al
    Erratum to "Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada" [Vaccine 92 (2026) 129122].
    Vaccine. 2026 Oct 31:129306. doi: 10.1016/j.vaccine.2026.129306.
    PubMed        


    Virology

  28. DUDIN GA, Alkubaisi NA, Aziz IM, Ikram A, et al
    The role of cytokines as immunological biomarkers of disease severity during respiratory syncytial virus (RSV) infection in children.
    Virology. 2027;625:111102.
    PubMed         Abstract available

Thursday, November 5, 2026

#Hantavirus #Outbreak Caused by #Andes Virus Linked to International Cruise #Ship #Travel — #USA, 2026

 


Abstract

Andes virus (ANDV), the only hantavirus known to be transmitted person-to-person, is endemic to areas of South America and can cause hantavirus pulmonary syndrome, which has a case-fatality rate of approximately 40%. On May 4, 2026, CDC was notified of seven cases of severe acute respiratory illness, including three deaths, among 147 persons aboard a cruise ship in the Atlantic Ocean; the illnesses were later confirmed to be caused by ANDV. No cases occurred among passengers who were U.S. residents. Ten of 28 U.S. resident passengers disembarked before ANDV infection was confirmed aboard the ship. On May 10, the remaining 18 U.S. resident passengers were repatriated to the National Quarantine Unit in Omaha, Nebraska, for risk assessment and monitoring, and where optimized advanced care was available, should symptoms develop. CDC and U.S. health departments monitored 60 additional U.S. residents potentially exposed on flights involving a passenger with symptomatic ANDV infection from the cruise, totaling 88 contacts across 27 jurisdictions. All 88 contacts completed 42 days of monitoring, with no secondary ANDV infections identified. Worldwide, local health authorities assessed and monitored approximately 653 potentially exposed persons from 33 countries. This response highlights the value of rapid coordination among partners to locate and monitor potentially exposed persons during an international outbreak to reduce the risk for ANDV transmission. Prompt notification to public health authorities can facilitate testing, patient care, contact identification, and implementation of measures to limit secondary transmission.


Source: Morbidity and Mortality Weekly Report, http://dx.doi.org/10.15585/mmwr.mm7543a1

____

Wednesday, November 4, 2026

#Andes virus on cruise #ships: An #evidence-stratified #review of #transmission risks and #biosecurity strategies

 


Abstract

The 2026 Andes virus (ANDV) cluster associated with the merchant vessel (MV) Hondius cruise ship highlights the limitations of hantavirus control strategies that have traditionally focused on rodent-source exposure alone. No evidence supports heating, ventilation, and air conditioning (HVAC)-mediated long-distance ANDV spread. Such strategies are insufficient for ecologically sensitive cruise routes, enclosed ocean-going environments, international passenger movement, and limited onboard medical capacity. Current evidence indicates that ANDV has limited but documented potential for person-to-person transmission. Transmission is most plausibly associated with acute-phase viremia, exposure to body fluids or short-range droplets, prolonged close contact, caregiving, and specific contextual conditions; it should not be equated with sustained community transmission by highly efficient respiratory viruses. On the basis of epidemiologic investigations, clinical shedding studies, animal models, viral genetic evidence, and environmental stability data, this review analyzes how high-consequence pathogens may have their public health impact amplified in cruise-ship settings. It further proposes prevention and control measures covering pre-voyage ecological exposure assessment, embarkation screening, early onboard recognition, tiered isolation, rapid shipboard testing, medical evacuation, and cross-border coordination. The central lesson from the MV Hondius event is that cruise ships operating on ecologically sensitive routes should move beyond conventional sanitation-centered management toward a whole-of-journey biosecurity model based on evidence stratification and graded response.


Source: Biosafety and Health Journal, https://doi.org/10.1016/j.bsheal.2026.07.006

____

#Serologic Evidence of Avian #Influenza Virus Exposure in #Livestock, #Egypt, 2024–2026

 


Abstract

Spillover of influenza A(H5N1) virus to cattle in the United States sparked global concern. We investigated whether endemic avian influenza viruses are potentially spilling over into domestic livestock in Egypt. We detected influenza H9N2 antibodies in 2.5% and H5N1 antibodies in 2.9%–4.5% of tested animals. Additional surveillance will elucidate host infection dynamics.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260869

____

#Fatal Disseminated #Powassan Virus #Infection in #Transplant Recipient, #Pennsylvania, #USA

 


Abstract

We describe histopathologic findings from a fatal case of Powassan virus lineage 2 (deer tick virus) in an immunosuppressed liver transplant patient in Pennsylvania, USA. We confirmed infection in postmortem brain, lung, and kidney by immunohistochemistry, in situ hybridization, and reverse transcription PCR, demonstrating infection of pulmonary and renal tissues.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260193

____

Tuesday, November 3, 2026

#Pathogenicity and #zoonotic potential of a novel pdm09-lineage #H1N2 swine #influenza A virus spatiotemporally linked to transboundary #pig trade

 


Abstract

International swine trade can disseminate influenza A viruses across borders, creating opportunities for reassortment with endemic swine viruses and the emergence of novel strains with zoonotic potential. Here, we characterize a novel H1N2 reassortant, A/swine/Korea/1030–3/2023 (1030–3), detected in South Korea and spatiotemporally associated with European swine lineages and international pig movement. 1030–3 harbors seven gene segments (PB2, PB1, PA, HA, NP, M and NS) closely related to a recent Danish zoonotic H1N1 virus of the 2009 pandemic (pdm09) lineage, and an N2 segment derived from an endemic Korean HxN2. In vitro assays demonstrated that 1030–3 preferentially bound human-type α2,6-linked sialic acid receptors and replicated efficiently in polarized human airway epithelial cells, although these properties were also observed in the endemic Korean H1N2 comparator 1027–1. In mice, 1030–3 caused moderate clinical signs and respiratory replication comparable to an early pdm09 reference strain NL09. In guinea pigs, 1030–3 transmitted to a subset of direct-contact animals but showed no detectable aerosol transmission under the conditions tested. In pigs, the natural host, 1030–3 replicated efficiently and transmitted to all direct-contact animals, with high respiratory shedding and a greater cumulative shedding burden in contact pigs than NL09. Contemporary human sera showed reduced neutralizing activity against 1030–3 relative to both human seasonal H1N1 and 1027–1, while antiserum against a recent H1N1 vaccine antigen also neutralized 1030–3 less efficiently. These findings identify a European-associated H1N2 swine influenza reassortant detected in South Korea that combines a distinct pdm09-derived genomic and antigenic background with efficient replication and transmission in pigs, α2,6-linked receptor preference, and reduced neutralization by human sera, underscoring the need for trade-aware surveillance of swIAVs and continued monitoring at the swine-human interface.


Source: PLoS Pathogens, https://doi.org/10.1371/journal.ppat.1014779

____

#Zoonotic Exposure to Porcine #Deltacoronavirus, #USA, 2019–2021

 


Abstract

Porcine deltacoronavirus (PDCoV) is a swine coronavirus with zoonotic potential. We detected PDCoV-neutralizing antibodies in 10 of 300 human serum samples; positive sample sources included 1 adult and 9 juveniles. Our findings provide evidence of human exposure to PDCoV and highlight the importance of monitoring animal coronaviruses with zoonotic potential.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260303

____

#CD8+ regulatory T cells limit #immunopathology but impair viral clearance in #Hantaan virus #infection

 


Abstract

In hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), virus-specific CD8+ T cells mediate both viral clearance and immunopathology. Here, we characterized a CD8+ regulatory T cell (Treg) subset restricted by HLA-E (and its murine ortholog Qa-1) in HFRS patients and in a murine HTNV infection model. CD8+ Tregs (CD122+Eomes+CD49dloKIR+), a subset substantially enriched for HLA-E-restricted T cells, were significantly reduced in peripheral blood of HFRS patients and displayed a terminally differentiated profile with elevated expression of KLRG-1, NKG2A, CTLA-4, and Fas-L, correlating with disease severity. Two HTNV glycoprotein-derived nonapeptides that bound Qa-1 were identified. Following immunization with the identified HTNV peptides and subsequent HTNV challenge, wild-type (WT) mice showed attenuated renal immunopathology, whereas D227K knock-in mice (with disrupted Qa-1-CD8/TCR interaction) showed enhanced viral clearance in the spleen and kidney but exacerbated renal immunopathology. Mechanistically, Qa-1-restricted CD8+ Tregs from WT mice suppressed effector CD8+ T cell proliferation in a peptide-specific, CD8/TCR-dependent manner via enhanced TGF-β secretion. Strikingly, D227K mutation dichotomously reshaped Treg phenotype: bulk polyclonal CD8+ Tregs displayed compensatory upregulation of inhibitory receptors (NKG2A, CTLA-4, PD-1) and TGF-β, whereas epitope-specific CD8+ Tregs showed impaired antigen-specific suppressive function and attenuated TGF-β production. Collectively, these findings indicate that HLA-E/Qa-1-restricted CD8+ Tregs can restrain immunopathology during HTNV infection, potentially at the cost of delayed viral elimination. Modulation of this axis may provide insights for therapeutic strategies in HFRS and related viral hemorrhagic fevers.

Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2536836123

____

Sunday, November 1, 2026

#H5N5 virus #transmission is driven by repeated cross-Atlantic introductions and transmission among high latitude #seabirds

 


Abstract

In November 2025, the first global H5N5 infection was reported in a person in Washington State. Previously, these viruses had only been detected in seabirds and shorebirds near the Atlantic Ocean, suggesting potentially distinct ecology from dominant H5N1 strains. Using 354 global H5N5 genomes, we show that H5N5 viruses have been carried by high latitude seabirds and shorebirds across the Atlantic at least 9 times, with introductions more frequent in the fall and spring. We reconstruct a plausible path of cross-continental movement via Arctic or sub-Arctic regions, followed by a year of cryptic circulation prior to human spillover. These data show that H5N5 viruses have undergone far more intercontinental movements than previously recognized, and exhibit host and geographic patterns that are fundamentally distinct from dominant H5N1 lineages. The distinct host ecology, geography, and movement, paired with the capacity to infect a person, suggest that enhanced surveillance may be warranted.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

National Institutes of Health, https://ror.org/01cwqze88, R01AI195533, 1F31AI202942-01, 75N93021C00016, U19AI181767

United States Department of Agriculture, SA-MZT-2023-065b


Source: BioRxIV, https://doi.org/10.64898/2026.10.29.762228

____

Saturday, October 31, 2026

#Coronavirus Disease Research #References (AMEDEO, Oct. 31 '26)

 


    Antiviral Res

  1. YAN D, Ma L, Chen J, Wu F, et al
    Nanobodies targeting the conserved post-fusion six-helix bundle core provide protective effects against SARS-CoV-2 infection and immunopathology.
    Antiviral Res. 2026 Oct 28:106562. doi: 10.1016/j.antiviral.2026.106562.
    PubMed         Abstract available

  2. BARBERO-URIZ O, Gonzalez-Rubio G, Valenti M, Molina M, et al
    Novel Nirmatrelvir-Resistance Mutations in SARS-CoV-2 Mpro Using a Yeast Screening Platform.
    Antiviral Res. 2026 Oct 26:106559. doi: 10.1016/j.antiviral.2026.106559.
    PubMed         Abstract available

  3. HAN Y, Zhang Q, Gao Y, Cao F, et al
    Divergent Functional Checkpoints Determine Epitope-Specific ADE Outcomes of SARS-CoV-2 Entry.
    Antiviral Res. 2026 Oct 26:106560. doi: 10.1016/j.antiviral.2026.106560.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  4. HANSON AW, Evans NJ, Pemmaraju SV, Ossai MS, et al
    Workroom contact networks: implications for COVID-19 and other respiratory infections.
    Infect Control Hosp Epidemiol. 2026 Oct 26:1-8. doi: 10.1017/ice.2026.10401.
    PubMed         Abstract available


    J Infect

  5. MORSE RB, Egan DJS, Cheng MTK, Altaf M, et al
    Mitigation of imprinted antibody responses against COVID-19 in highly vaccinated older adults.
    J Infect. 2026 Oct 30:106883. doi: 10.1016/j.jinf.2026.106883.
    PubMed         Abstract available

  6. HOFFMANN M, Zhang L, Chen N, Moor N, et al
    Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1.
    J Infect. 2026 Oct 24:106886. doi: 10.1016/j.jinf.2026.106886.
    PubMed        


    J Med Virol

  7. FRICKE-GALINDO I, Ortega-Villafuerte FM, Perez-Rubio G, Buendia-Roldan I, et al
    Plasma Interleukin-10 Levels and IL10 Genetic Variants Are Associated With Clinical Outcomes in Patients With Severe COVID-19 Treated With Corticosteroids.
    J Med Virol. 2026;98:e71201.
    PubMed         Abstract available

  8. BRAMANTE CT, Sturmer T, Huling JD, Buse JB, et al
    Metformin at the Time of COVID-19 Infection and Risk of Long COVID: A Target Trial Emulation Study.
    J Med Virol. 2026;98:e71190.
    PubMed         Abstract available

  9. YIN J, Huang X, Ou X, Xu S, et al
    Early Risk Stratification of COVID-19 Associated Cytokine Storm Using a Four-Cytokine Cumulative Score: A Retrospective Cohort Study.
    J Med Virol. 2026;98:e71191.
    PubMed         Abstract available


    J Virol

  10. COLARUSSO A, Stephenson KE, Collier A-RY, Wegmann F, et al
    Early innate immune signatures correlate with Ad26.COV2.S vaccine immunogenicity and protective efficacy.
    J Virol. 2026 Oct 26:e0149426. doi: 10.1128/jvi.01494.
    PubMed         Abstract available


    Lancet

  11. CATTO JWF, Thomson RM, Griffith DM, Mavhu W, et al
    A global men's health epidemiology within an intersectional framework.
    Lancet. 2026;408:1881-1898.
    PubMed         Abstract available


    N Engl J Med

  12. PRENTICE LR, Sadler LC, Anderson KL, Wilkinson JD, et al
    In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility.
    N Engl J Med. 2026 Oct 27. doi: 10.1056/NEJMoa2602728.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Oct. 31 '26)

 


    Arch Virol

  1. GUDYMO AS, Kolosova NP, Panova AS, Shadrinova KN, et al
    Contact transmission of fur seal-derived genotype A3 influenza A(H5N1) virus in ferrets.
    Arch Virol. 2026;171:313.
    PubMed         Abstract available


    Epidemiol Infect

  2. KONSTANTOPOULOU A, Velali K, Markopoulou P, Anastasiadou A, et al
    Impact of national RSV immunization programme on the epidemiology of bronchiolitis in Greece.
    Epidemiol Infect. 2026;154:e143.
    PubMed         Abstract available

  3. HAYES B, Lamielle G, Moon M, Padungtod P, et al
    Effectiveness of live-animal and environmental samples for detecting high pathogenicity avian influenza viruses in live-bird markets in Southeast Asia, 2015-2022.
    Epidemiol Infect. 2026 Oct 28:1-24. doi: 10.1017/S0950268826102246.
    PubMed        

  4. PLANCHAND S, Nivoix C, Fischer EAJ, Vergne T, et al
    Divide and reduce: systematic review and mathematical modelling of the impact of within-farm compartmentalisation on avian influenza transmission in poultry.
    Epidemiol Infect. 2026 Oct 27:1-30. doi: 10.1017/S0950268826102350.
    PubMed        

  5. SCOTT M, Browning L, Roberts T, De Boer J, et al
    An investigation into post-pandemic ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations.
    Epidemiol Infect. 2026;154:e139.
    PubMed         Abstract available


    J Clin Microbiol

  6. SHU B, Liddell J, Wong P, Duron ES, et al
    Update to the CDC influenza A(H3) subtyping assay for improved detection of influenza A(H3N2) viruses, including subclade K viruses.
    J Clin Microbiol. 2026 Oct 27:e0072726. doi: 10.1128/jcm.00727.
    PubMed         Abstract available


    J Immunol

  7. CHANG LA, Burgess E, Noureddine M, Wells AJ, et al
    Vaccine immunity can drive eosinophil recruitment in influenza breakthrough infection with mouse strain-specific outcomes.
    J Immunol. 2026;215:vkag279.
    PubMed         Abstract available


    J Virol

  8. FARRUKEE R, Xia Y, Morris R, Barnes JB, et al
    Bovine myxovirus resistance protein (Mx)1, but not Mx2, mediates antiviral activity against human and avian influenza A viruses, including H5N1 clade 2.3.4.4b.
    J Virol. 2026 Oct 28:e0137226. doi: 10.1128/jvi.01372.
    PubMed         Abstract available


    PLoS One

  9. ABDOLLAHI K, Rezaei Ghahroodi Z, Mansourian M
    Causal discovery and inference in COVID-19: A multiscale longitudinal analysis using mixtures of DAGs.
    PLoS One. 2026;21:e0355553.
    PubMed         Abstract available

  10. ZHANG L, Ton B, Mewton L, Schweizer S, et al
    Alcohol use and its associations with mental health across the first year of the COVID-19 pandemic.
    PLoS One. 2026;21:e0361854.
    PubMed         Abstract available

  11. TIAN Y, Richards DK, Cox MJ
    Temporal and seasonal trends in public interest in nonalcoholic beverages and lifestyles: A Google Trends analysis, 2004-2026.
    PLoS One. 2026;21:e0361032.
    PubMed         Abstract available

  12. BHUIYAN MRI, Sayem MA, Makhdum N
    Understanding the influencing factors of telemedicine service adoption in post-pandemic Bangladesh: An extended TAM and UTAUT2 model analysis.
    PLoS One. 2026;21:e0361691.
    PubMed         Abstract available

  13. STENGLER AL, Mattern E, Ronellenfitsch U, Steckelberg A, et al
    Experiences and challenges of healthcare professionals in oncological surgery during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2026;21:e0361492.
    PubMed         Abstract available

  14. INUSAH AS, Xia H, Pasha A, Li Z, et al
    Longitudinal changes in BMI and obesity across COVID-19 pandemic periods among underrepresented populations: An analysis of the All of Us dataset.
    PLoS One. 2026;21:e0360745.
    PubMed         Abstract available

  15. HABIB MI, Sayeed MA, Islam M, Sarker MFR, et al
    Epidemiological characterization of avian influenza virus circulation in pigeons and quail across different production systems in Chattogram, Bangladesh.
    PLoS One. 2026;21:e0361561.
    PubMed         Abstract available

  16. MORITA T, Elsayed AMA, Hirakawa R, Lawal-Ayinde BM, et al
    Impact of low temperature on the efficacy of chlorous acid water and sodium hypochlorite solution for inactivating avian influenza virus on material surfaces.
    PLoS One. 2026;21:e0360392.
    PubMed         Abstract available

  17. GARCES-ARILLA S, Fidalgo C, Mendez-Lopez M, Hidalgo V, et al
    Health-related quality of life in women and men with long COVID.
    PLoS One. 2026;21:e0357749.
    PubMed         Abstract available

  18. SIMKHADA P, Lwin KS, Koirala B, Shrestha A, et al
    Barriers and facilitators of evidence-informed health policymaking in Nepal: A scoping review.
    PLoS One. 2026;21:e0358730.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  19. TURELLI P, Eray E, Raclot C, Trono D, et al
    Antigenic landscape of a highly mutated SARS-CoV-2 spike in ongoing viral evolution.
    Proc Natl Acad Sci U S A. 2026;123:e2608185123.
    PubMed         Abstract available

  20. NILFOROSHAN H, Reisler J, Jahanparast E, Moor M, et al
    Revised estimates of types and duration of long COVID symptoms based on claims records from 245 million US patients.
    Proc Natl Acad Sci U S A. 2026;123:e2604414123.
    PubMed         Abstract available


    Vaccine

  21. HUMBLE RM, Reifferscheid L, Gilbert NL, Dube E, et al
    Differences between Canadian parents' attitudes toward routine, influenza, and COVID-19 vaccines for their children, and changes in vaccine hesitancy since the pandemic: A national cross-sectional comparative study.
    Vaccine. 2026;96:129300.
    PubMed         Abstract available

  22. ZHANG J, Shen Y, Shi W, Ma J, et al
    End-of-season influenza vaccine effectiveness against a(H3N2) and B/Victoria in Beijing, China, 2025/26 season.
    Vaccine. 2026;96:129273.
    PubMed         Abstract available

  23. CHENG C, Chen X, Ge Y, Sung MH, et al
    Faster waning of immunity to influenza vaccine strains reintroduced into subsequent seasons: A human cohort study.
    Vaccine. 2026;95:129258.
    PubMed         Abstract available

  24. MISHIN VP, Patel MC, Gao R, Grant L, et al
    Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18-64?years.
    Vaccine. 2026;95:129281.
    PubMed         Abstract available

  25. CAI Z, Wang L, Ji S, Deng X, et al
    Quantifying the impact of pathogen interactions on vaccine effectiveness estimates in the test-negative design.
    Vaccine. 2026;94:129265.
    PubMed         Abstract available

  26. YAMAMOTO S, Matsuda K, Maeda K, Mizoue T, et al
    Protection of Omicron XBB.1.5 vaccine, previous infection, and their induced neutralizing antibodies against symptomatic SARS-CoV-2 infection during Omicron KP.3 wave.
    Vaccine. 2026;94:129242.
    PubMed         Abstract available

  27. MENEZES APO, Leite JLP, Pimenta FC, Larson S, et al
    Pneumococcal carriage and selected respiratory virus in children with clinical pneumonia in Salvador, Brazil during PCV10 era.
    Vaccine. 2026;94:129241.
    PubMed         Abstract available

  28. ISHII H, Miyauchi K, Harada S, Nakamura-Hoshi M, et al
    Intranasal immunization expressing S1 antigen can confer functionally sterile protection against an intranasal SARS-CoV-2 challenge in mice.
    Vaccine. 2026;94:129259.
    PubMed         Abstract available

  29. MAYR W, Knell AI, Boehm AK, Jager M, et al
    Longitudinal SARS-CoV-2 mRNA vaccine immunogenicity in inflammatory bowel disease in relation to anti-TNF therapy and age: a prospective cohort study.
    Vaccine. 2026;94:129224.
    PubMed         Abstract available

  30. MALIBWA D, Lees S, Ewing V, Deogratias D, et al
    Influence of COVID-19 and COVID-19 rumours on trust and uptake of single-dose male HPV vaccination in the Add-Vacc cluster-randomised trial, northwest Tanzania.
    Vaccine. 2026;94:129231.
    PubMed         Abstract available

  31. TOME J, Schwind JS, Richmond HL, Deloach B, et al
    Vaccine recipient and volunteer experiences from COVID-19 mass vaccine clinics at a university campus: drive-through and walk-through approaches.
    Vaccine. 2026;94:129229.
    PubMed         Abstract available

  32. PRASERT K, Nakphook S, Kittiwatanachod J, Ditsungneon D, et al
    Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 mug HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA.
    Vaccine. 2026;94:129230.
    PubMed         Abstract available


    Virology

  33. ARSANA A, Zhu W, Kang SM, Wang BZ, et al
    Towards influenza vaccine universality: Smart vaccine regimens and adjuvant-driven germinal center responses.
    Virology. 2026;625:111110.
    PubMed         Abstract available

  34. SEGALIN JT, Weiss M, de Almeida G, Lenhard BF, et al
    Genotypic and phenotypic characterization of the main endemic swine influenza A virus subtypes in Brazil.
    Virology. 2026;625:111099.
    PubMed         Abstract available

  35. ISAKOVA-SIVAK I, Matyushenko V, Rudenko L
    Influenza viruses as vaccine vectors: Historical background and future directions.
    Virology. 2026;625:111105.
    PubMed         Abstract available

Molecular #Surveillance for #Oropouche, #Mayaro, West Nile, and Saint Louis #Encephalitis Viruses, #Brazil, 2019–2025

 


Abstract

To assess the circulation of Oropouche, Mayaro, West Nile, and St. Louis encephalitis viruses, we tested samples from 824 patients with acute febrile illness, 3,484 mosquitoes, and 113 nonhuman primates from northern Minas Gerais, Brazil. All samples were negative for dengue, Chikungunya, and Zika virus. One imported Oropouche virus infection was detected.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260870

____

Friday, October 30, 2026

Comparative #Distribution of α2,3- and α2,6-Linked Sialic Acid #Receptors and #Influenza #H5N1 Virus #Binding in #Sheep, #Goats, and #Alpacas

 


ABSTRACT

Highly pathogenic avian influenza virus (HPAIV) H5N1 continues to pose a significant threat to animal and human health. Since 2022, an expanded host range has been observed, as illustrated by the H5N1 outbreak in dairy cows. Other minor livestock species, such as sheep, goats, and alpacas, have also tested positive for H5N1 for the first time, raising concerns about its impact on previously overlooked livestock species. In this study, we first characterized the distribution of sialic acid (SA) receptors across respiratory and non-respiratory tissues of sheep, goats, and alpacas using Maackia amurensis (SA α2,3) and Sambucus nigra (SA α2,6) lectins. We found that both SA receptors are present in all tissues across species, with notable differences in their distribution and abundance. Next, we developed recombinant LPAIV H5N1 viruses over a laboratory-adapted backbone to evaluate tissue-specific virus binding profiles. The results show that a representative H5N1 virus from clade 2.3.4.4b binds effectively to respiratory and non-respiratory tissues across all species. The strongest virus binding was observed in sheep, followed by goats and, lastly, alpacas. Similar binding patterns were observed with an LPAIV version of clade 2.3.4.4b and a Gs/Gd lineage precursor prototype virus. Finally, we show that H1N1 and H3N2 viruses also bind to respiratory tissues of sheep and goats. These findings provide important insights into the potential susceptibility of minor livestock species to HPAIV H5N1 and other influenza subtypes. Our results contribute to a better understanding of influenza tissue tropism across livestock species and its potential implications for zoonotic transmission.


IMPORTANCE 

Since 2022, an unprecedented number of Influenza A virus (IAV) H5N1 detections have been reported in mammals. Sheep, goats, and alpacas are often raised in integrated production systems and may serve as hosts at the wildlife-livestock interface. The establishment of H5N1 in any mammalian host also increases its pandemic potential. Our results reveal species- and tissue-dependent patterns of H5N1 attachment and identify tissues that support viral binding. Furthermore, we show that respiratory tissues may be susceptible to other IAV subtypes, suggesting that these species could act as mixing vessels for reassortment events and the emergence of novel IAV strains. These results expand our understanding of the host range and tissue tropism of H5N1 and other IAV subtypes, providing a foundation for targeted surveillance of minor livestock species. Collectively, this work underscores the importance of considering diverse livestock hosts when evaluating the continued spread of H5N1 at the avian-mammalian interface.


Competing Interest Statement

The authors have declared no competing interest.


Source: BioRxIV, https://doi.org/10.64898/2026.10.26.762033

____

Provincial #Index Case of #Bundibugyo #Ebolavirus Disease in South Kivu Province, #DRC, 2026: A Case Report

 


Abstract

The ongoing second-largest Ebola outbreak in the Democratic Republic of the Congo (DRC) was caused by contagious Bundibugyo virus (BDBV). So far, seven provinces of the DRC including Bas-Uele, Haut-Uele, Ituri, Nord-Kivu (North Kivu), Sud-Kivu (South Kivu), Sud-Ubangi (South Ubangi), and Tshopo provinces have confirmed cases of BDBV. Here, we report the clinical characteristics of the provincial index case of BDBV 2026 infection in South Kivu, DRC, and provide information about contacts who tested positive for BDBV. Collected clinical specimens tested with Polymerase Chain Reactions confirmed BDBV in the infected index case and its connections.

Source: Viruses Journal, https://doi.org/10.3390/v18111204

____

My New Space

Most Popular Posts